FDA Inspections: Uncovering Blind Spots

Blind spots in your Quality Management System can cripple operations, endanger patients, and trigger devastating enforcement actions. Gain insights on the "why" behind the most common deficiencies encountered during FDA inspections, and learn risk-based strategies that deliver immediate, actionable results.

Experts: Phil Pontikos (Former FDA National Expert and Investigator) and Ben Dastoli (Former FDA Investigator and Specialist)

Recording: Access the Recording and Slides